Document is current
Any future updates will be listed below
-
Authors
Cavuoto, Riccardo
Damian, Sofia
Deseri, Luca
Fraldi, Massimiliano
Siesky, Brent
Verticchio, Alice
Harris, Alon
Guidoboni, Giovanna
-
Funding
Funding for this research was provided by:
Ministero dell’Università e della Ricerca (ID 62053)
European Research Council (ERC-ADG-2021- 101052956-BEYOND)
Horizon 2020 Framework Programme (SUBBIMATT Horizon Europe EU HE GA 101129911)
Ministero dell’Università e della Ricerca, Italy (PRIN-2022ATZCJN)
National Institutes of Health (R01EY034718)
Università degli Studi di Napoli Federico II
- License Information
-
More Information
Article History
Received: 11 November 2025
Accepted: 16 May 2026
First Online: 22 June 2026
Declarations
:
: Professor Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris and SlitLed. Professor Alon Harris holds an ownership interest in AdOM, Oxymap, Qlaris, SlitLed, and AEYE Health. If you have questions regarding paid relationships that your physician/researcher may have with industry, you are encouraged to talk with your physician/researcher, or check for industry relationships posted on individual faculty pages on our website at .
